Cardiac Science (Irvine, California), a maker of automated external defibrillators (AEDs), has entered into an expanded alliance with privately held Complient Corp. (Solon, Ohio), an outsource provider of workplace AED programs, to roll out a private-label workplace defibrillation program consisting of AED training, medical direction, customer support and Internet-based software services aimed at Cardiac Science's corporate AED customers. Cardiac Science plans to package these services along with its AEDs and offer corporate customers these services under multi-year contracts.
Cook (Bloomington, Indiana) has been awarded a two-year supplier agreement by Premier (San Diego, California), one of the nation's largest not-for-profit hospital alliances, for an offering of diagnostic and interventional products. The new agreement provides Premier members with a wide range of interventional radiology products and services offered by Cook, whose companies are involved in interventional radiology, interventional cardiology, urology, neuroradiology, vascular medicine, critical care and other growing diagnostic and therapeutic specialties.
Curis (Cambridge, Massachusetts) has completed a transaction under the terms of which Stryker (Kalamazoo, Michigan) will purchase the right to eliminate its future royalty obligations for P-7 (OP-1) for $14 million in cash. In addition to obtaining immediate receipt of its future BMP-7 royalties, the agreement allows Curis to reduce future BMP-7 royalties owed Stryker for products in therapeutic indications other than orthopedics and dental. Daniel Passeri, president and CEO of Curis, said the transaction provides several benefits to his company. "We obtain immediate access to cash, thus allowing us an extended runway for development of Curis product initiatives. In addition, the royalty reduction provides Curis added flexibility to develop its BMP-7 programs in kidney disease and other non-orthopedic fields."
Inamed (Santa Barbara, California), a global medical device company developing products for breast and facial aesthetics and obesity intervention, and Genzyme Biosurgery (Cambridge, Massachusetts) unveiled an agreement giving Inamed the exclusive rights to market and sell Genzyme Biosurgery's hyaluronic acid-based dermal filler products Hylaform, Hylaform Plus and Hylaform Fine Line in the U.S. Inamed already successfully commercializes these products in Europe and Canada through its Inamed Aesthetics unit. Under the terms of this transaction, Inamed and Genzyme will participate together in the clinical and regulatory activities necessary to obtain FDA clearance. Genzyme will receive payments from Inamed upon the achievement of Hylaform development milestones and will be entitled to receive transfer and royalty payments in connection with Hylaform product sales. Hylaform is an injectable viscoelastin hylan gel being investigated for the correction of facial wrinkles and depressed scars.
Invivo (Pleasanton, California) said that its wholly owned subsidiary, Invivo Research, has entered into an exclusive distribution agreement with Draeger Medical (Telford, Pennsylvania), a provider of medical systems and services for anesthesia. This agreement provides for the sale of the Draeger Medical Narkomed MRI-2 anesthesia system through Invivo Research's direct sales force in the U.S. and distributor network in Canada. Invivo Research will market the anesthesia delivery system as Magnitude(AS) in combination with its existing Magnitude MRI patient monitoring product line.
Mobile PET Systems (San Diego, California), a provider of positron emission tomography (PET) imaging services to health care entities, and Bracco Diagnostics (Princeton, New Jersey) the U.S. operating company of the Bracco Group (Milan, Italy), have agreed to establish a strategic partnership pilot program designed to jointly provide cardiac PET products and services to healthcare providers. Under this pilot program Bracco Diagnostics and Mobile PET Systems have agreed to combine their marketing and sales resources to offer cardiovascular PET services to U.S. cardiology groups.
Siemens Medical Solutions (Erlangen, Germany) and R2 Technology (Sunnyvale, California), a developer of computer-aided detection (CAD) and visualization technology, have entered into a development and license agreement to customize and market CAD technology for use with Siemens' computed radiography (CR) and full-field digital mammography (FFDM) equipment. R2's CAD technology assists radiologists in the early and more accurate detection of breast cancer and other cancer-related lesions. Siemens will have sole worldwide distribution rights for three years to its CR-based and flat-detector based FFDM systems integrated with R2's CAD technology. The combination of the two devices will require FDA approval for use in the U.S. The R2 ImageChecker system was approved by the FDA in 1998 for use with film-based screening mammography to assist in minimizing false negative readings.
Visx (Santa Clara, California) said it has entered into an exclusive worldwide license agreement for a portfolio of patents held by Luis Ruiz, MD, relating to the treatment of presbyopia with multifocal ablations. Visx has clinical studies under way to develop an effective laser treatment for presbyopia. Visx also said it has signed a letter of intent with Tracey Technologies for exclusive worldwide rights to Tracey's ray tracing technology for use in customized laser vision correction treatments.